Chlordiazepoxide (5mg) + Clidinium (2.5mg) + Dicyclomine (10mg) + Rabeprazole (10mg) (Medical Monograph)

Overview

A fixed-dose combination (FDC) product designed for the comprehensive management of acid-peptic disorders, particularly those complicated by anxiety, visceral hyperalgesia, and significant smooth muscle spasm. It combines a benzodiazepine anxiolytic (Chlordiazepoxide), two anticholinergic/antispasmodic agents (Clidinium & Dicyclomine), and a Proton Pump Inhibitor (Rabeprazole). This combination is intended to address the 'brain-gut axis' dysfunction often seen in functional gastrointestinal disorders like Irritable Bowel Syndrome (IBS) and severe, stress-aggravated gastroduodenal ulcers. It is a potent formulation reserved for specific clinical scenarios where monotherapy or simpler combinations are insufficient.

This combination employs a multi-target approach: 1) Rabeprazole provides profound and sustained gastric acid suppression by irreversibly inhibiting the H+/K+ ATPase (proton pump) in gastric parietal cells. 2) Dicyclomine and Clidinium act as antimuscarinic agents, blocking acetylcholine at smooth muscle M3 receptors in the GI tract, reducing motility, secretion, and relieving spasm/pain. Dicyclomine may also have a direct smooth muscle relaxant effect. 3) Chlordiazepoxide acts centrally as a benzodiazepine, potentiating GABA-A receptor-mediated inhibitory neurotransmission, reducing anxiety and the central component of visceral hypersensitivity.